BioMarin agreed to buy Alesta Therapeutics in a deal valued at $275 million upfront, bringing the hypophosphatasia program into BioMarin’s skeletal disease portfolio. The transaction is designed to restock a pipeline in a commercially defined rare bone segment and strengthen the company’s ability to compete as larger rivals target rare metabolic and skeletal disorders. The announcement aligns with BioMarin’s broader strategy of adding mid-to-late stage assets and expanding patient reach across bone and muscle conditions. Analysts will likely scrutinize how BioMarin intends to sequence development work, whether the acquisition changes near-term catalysts, and how the program complements existing skeletal franchise efforts. The Alesta buyout also signals continued appetite among cash-generative rare disease specialists for bolt-on assets that can extend franchise duration against competitive pressures.